Puma Biotechnology (PBYI) Stock Price
Puma Biotechnology Price
Over the last 8 years Puma Biotechnology grew revenue by 30.2% annually, reaching 228.37 M USD. Earnings per share have grown at 2,300.5% per year over the last 3 years. For Puma Biotechnology, the net margin of 13.6% is up versus -11.5% a few years ago. The consensus 12-month price target for Puma Biotechnology is 5.10 USD, about 49.4% below where the stock trades today. Of 6 analysts, 0 rate the stock a buy — an overall Sell consensus.
Puma Biotechnology stock price
Puma Biotechnology business model & stock analysis
Frequently asked questions about Puma Biotechnology
The business model of Puma Biotechnology Inc. is focused on developing and commercializing innovative treatments for cancer. The company specializes in the research and development of targeted therapies that aim to address specific types of cancer, such as HER2-positive breast cancer. Puma Biotechnology Inc. is committed to advancing the field of oncology through the discovery and development of effective and safe medications. By utilizing its expertise in molecular biology and drug development, the company aims to improve patient outcomes and contribute to the fight against cancer. Puma Biotechnology Inc. strives to create value for its shareholders by bringing novel treatments to market and maintaining a strong pipeline of innovative therapies.
Puma Biotechnology Inc is primarily active in the biotechnology industry.
The main competitors of Puma Biotechnology Inc in the market include well-established pharmaceutical companies such as Pfizer, Novartis, and Roche. These companies also focus on developing and commercializing innovative treatments for various diseases, including cancer. Puma Biotechnology Inc faces competition in its targeted therapy segment, particularly in the field of HER2-positive breast cancer treatment, where these competitors have their own competing products. However, Puma Biotechnology Inc's unique drug development pipeline and its focus on personalized medicine allow it to differentiate itself in the market.
Puma Biotechnology Inc. is a renowned biopharmaceutical company with a rich history and background. Established in 2010, Puma Biotechnology primarily focuses on the development and commercialization of innovative therapeutics to treat various forms of cancer. Headquartered in Los Angeles, California, the company has successfully developed and received approvals for its flagship product, Nerlynx (neratinib), which is utilized in the treatment of HER2-positive breast cancer. Recognized for its cutting-edge research and development efforts, Puma Biotechnology strives to provide advanced treatment options and improve the lives of cancer patients worldwide. With a commitment to pioneering medical breakthroughs, Puma Biotechnology continues to leave a significant impact in the field of oncology.
Puma Biotechnology Inc has achieved several significant milestones. One of the notable achievements includes the successful development and commercialization of Nerlynx (neratinib), an FDA-approved treatment for HER2-positive breast cancer. Additionally, Puma Biotechnology Inc has made substantial progress in conducting clinical trials and expanding the indications for Nerlynx. The company has also advanced its research pipeline, collaborating with leading institutions to explore potential therapies for various types of cancer. Puma Biotechnology Inc's commitment to innovation and patient-centric approach has positioned them as a key player in the biotechnology industry.
Puma Biotechnology Inc is primarily present in the United States.
Puma Biotechnology Inc represents a strong commitment to improving the lives of patients battling cancer. The company's corporate philosophy centers around advancing innovative treatments and therapies to combat various forms of cancer. Puma Biotechnology is dedicated to conducting rigorous research and development to bring effective, cutting-edge medicines to market. With a focus on personalized medicine, Puma Biotechnology strives to tailor treatments to patients' specific needs, enhancing their chances of positive outcomes. By harnessing scientific advancements and collaborating with leading experts, Puma Biotechnology remains steadfast in its mission to make a meaningful impact in the fight against cancer.
Analysts currently set an average price target of 5.10 USD for the Puma Biotechnology stock (median: 5.10 USD), implying -49.4 % versus the latest price. The consensus is based on 6 analyst ratings.
6 analysts currently rate the Puma Biotechnology stock: 0 recommend buying, 3 holding and 3 selling. For 2026, analysts expect Puma Biotechnology to generate revenue of 226.00 M USD and earnings per share of 0.37 USD.
Converted at the current exchange rate, the Puma Biotechnology share trades at 9.00 EUR (10.08 USD).
The Puma Biotechnology share (PBYI) is listed on 1 stock exchanges, including: NASDAQ (PBYI).
Puma Biotechnology Inc is an American biotech company that focuses on the development of innovative cancer therapies. It was founded in 2010 and is headquartered in Los Angeles, California. Puma Biotechnology operates in two business segments: drug development and commercialization of drugs. The primary business unit focuses on the development of cancer drugs. The flagship product of Puma Biotechnology is Neratinib, an oral cancer medication used for the treatment of HER2-positive breast cancer. Other clinical studies are also underway, including PB272, another oral cancer medication for the treatment of HER2-positive breast cancer and other types of cancer. In addition to drug development, Puma Biotechnology also engages in the commercialization of drugs, marketing Neratinib in the US, Europe, and Asia in collaboration with various partners. The company works closely with medical communities and patient organizations to raise awareness of the latest treatment options and increase the availability of medications in different countries. Puma Biotechnology also collaborates with scientific and clinical organizations to advance the development of innovative cancer therapies. The company aims to develop and bring to market patient-centric cancer therapies that can improve the quality of life for cancer patients. Puma Biotechnology plans to increase its research and development activities, expand its product range to cover more types of cancer, and expand into new markets while increasing production capacity to meet higher demand for its products. Overall, Puma Biotechnology Inc has a strong business model based on successful development of cancer medications and a strong commercial presence. The company's future prospects are promising as it focuses on the direct needs of cancer patients and strives to develop innovative therapies that have the potential to improve the lives of millions of patients worldwide.
The expected revenue of Puma Biotechnology is 226.00 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Puma Biotechnology is 19.15 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Puma Biotechnology is currently 27.13. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Puma Biotechnology stock.
The price-to-sales ratio (P/S) of Puma Biotechnology is currently 2.30. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Puma Biotechnology stock.
The Eulerpool Quality Score for Puma Biotechnology is 5/10.
The ISIN of Puma Biotechnology is US74587V1070. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Puma Biotechnology is A1J643. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Puma Biotechnology is PBYI. The ticker symbol is used to trade Puma Biotechnology shares on the stock exchange.
Puma Biotechnology stock
Puma Biotechnology Peer Group
Puma Biotechnology Ticker
Puma Biotechnology FIGI
All fundamentals and in-depth analysis of Puma Biotechnology
Our stock analysis for Puma Biotechnology stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Puma Biotechnology. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.